Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Combination of genetics at baseline and clearance of MRD to assign the post-remission treatment of patients with Philadelphia-negative ACUTE lymphoblastic leukemia. FINAL results of pethema LAL19 trial

Anna Torrent, Mireia Morgades, Susana Barrera, Jordi Ribera, Eulàlia Genescà, José González-Campos, Nuria Martinez-Cibrian, Pau Montesinos, Alberto Hernández-Sánchez, Pere Barba, Edgar Zapico, Ricardo Sanchez, Marta Sitges Arriaga, Clara Maluquer Artigal, Esperanza Such, Carmen Botella, Maria Queipo De Llano, Mónica Cabrero Calvo, Ana Maria Vicent Castelló, Paula Lopez de Ugarriza, Mar Tormo, Bernardo Gonzalez Gonzalez, Irene García-Cadenas, Carlos Rodriguez Medina, Pilar Martínez-Sánchez, Arancha Bermúdez, Ignacio Gómez-Centurión, María Herrero García, Juana Ciudad, María Hermosín-Ramos, Josefina Serrano, Jose Angel Raposo Puglia, Laura Solán Blanco, Verónica Roldán Galiacho, María Almudena De Laiglesia Lorenzo, Lucía Gómez Pérez, María Solé Rodriguez, Mará Sol Casado Calderón, Laura Llorente González, Daniel Barrios Decoud, Ferran Vall-Llovera Calmet, Lorenzo Algarra, María Lourdes Amador Barciela, Raimundo Garcia, Antonia Cladera Serra, Juan Miguel Bergua Burgues, Isabel Granada, Jesus Maria Hernandez Rivas, Alberto Orfao, Josep-Maria Ribera

Blood (2025) 146 (Supplement 1): 5121.

https://doi.org/10.1182/blood-2025-5121

Published: 2025

Journal Articles

Excellent prognosis for adult patients with Philadelphia chromosome-negative ALL with standard genetic risk and EARLY clearance of MRD. sub-analysis of pethema LAL19 trial

Blood (2025) 146 (Supplement 1): 1564.

https://doi.org/10.1182/blood-2025-1564

Published: 2025

Journal Articles

AI-based classification and outcome prediction in BCR::ABL1-like B-cell precursor acute lymphoblastic leukemia patients using targeted RNA-seq

Juan Manuel Rosa-Rosa, Jordi Ribera, Mireia Morgades, Isabel Granada, Rosa Ayala Diaz, Susana Barrera, Alberto Hernández-Sánchez, Josgrey Del Valle Navas Acosta, María Herrero García, Esperanza Such, Anna Torrent, Rosa Coll, Marta Cervera, Clara Maluquer Artigal, Jesus Maria Hernandez Rivas, Alberto Orfao, Josep-Maria Ribera, Joaquin Martinez-Lopez, Ricardo Sanchez

Blood (2025) 146 (Supplement 1): 4358.

https://doi.org/10.1182/blood-2025-4358

Published: 2025

Journal Articles

Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial

Blood (2024) 144 (Supplement 1): 1437.

https://doi.org/10.1182/blood-2024-207954

Published: 2024

Journal Articles

Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial

Blood (2024) 144 (Supplement 1): 962.

https://doi.org/10.1182/blood-2024-205124

Published: 2024

Journal Articles

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1461.

https://doi.org/10.1182/blood-2023-186265

Published: 2023

Journal Articles

Mutually-Exclusive Pathways between IKZF1 plus and RAS Mutations and TP53 double-Hit Alterations Lead Relapse in B-Other, Ph-like and Hyperdiploidy Genetic Groups in Adult B-Cell Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1616.

https://doi.org/10.1182/blood-2023-182163

Published: 2023

Journal Articles

CD34 + CD19 − CD22 + B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

Blood (2022) 140 (1): 38–44.

https://doi.org/10.1182/blood.2021014840

Published: 2022

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Combination of genetics at baseline and clearance of MRD to assign the post-remission treatment of patients with Philadelphia-negative ACUTE lymphoblastic leukemia. FINAL results of pethema LAL19 trial

Excellent prognosis for adult patients with Philadelphia chromosome-negative ALL with standard genetic risk and EARLY clearance of MRD. sub-analysis of pethema LAL19 trial

AI-based classification and outcome prediction in BCR::ABL1-like B-cell precursor acute lymphoblastic leukemia patients using targeted RNA-seq

Similar Outcome of Adolescents and Young Adults (AYA) and Older Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) without Philadelphia Chromosome (Ph-) Included in the Pethema LAL-2019 Trial

Prognostic Impact of the Genetic Risk at Baseline Associated to the MRD Clearance in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Preliminary Results of Pethema LAL19 Trial

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Mutually-Exclusive Pathways between IKZF1 plus and RAS Mutations and TP53 double-Hit Alterations Lead Relapse in B-Other, Ph-like and Hyperdiploidy Genetic Groups in Adult B-Cell Acute Lymphoblastic Leukemia

CD34 + CD19 − CD22 + B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only